Ascendis Pharma announces online portal open to request access to TransCon PTH

Ascendis Pharma announced that the online portal is now open for physicians wanting to request access to TransCon PTH, the Company’s investigational parathyroid hormone replacement therapy, through the U.S. Expanded Access Program. To qualify, patients must be adults diagnosed with hypoparathyroidism who live in the U.S., have prior PTH treatment experience, and meet other criteria outlined below and in the full treatment protocol. "We are pleased to have worked with the FDA to make TransCon PTH available for eligible patients in the U.S.," said Edward Trott, M.D., Vice President, Global Medical Affairs at Ascendis Pharma. "Recognizing the needs expressed by the hypopara community, we will continue to work with the FDA and others to make TransCon PTH, if approved, more broadly available as quickly as possible."